Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion.
作者信息
Jädersten Martin
出版信息
Haematologica. 2010 Mar;95(3):348-51. doi: 10.3324/haematol.2009.019141.
Abstract
摘要
相似文献
1
Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion.
Haematologica. 2010 Mar;95(3):348-51. doi: 10.3324/haematol.2009.019141.
2
[The 5q- syndrome].
Rev Prat. 2010 Dec 20;60(10):1420-2.
3
Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion.
Ann Hematol. 2012 Feb;91(2):309-10. doi: 10.1007/s00277-011-1263-7. Epub 2011 May 28.
4
Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.
Leuk Res. 2011 Sep;35(9):e175-6. doi: 10.1016/j.leukres.2011.05.020. Epub 2011 Jun 11.
5
Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.
Leuk Res. 2011 Sep;35(9):1276-8. doi: 10.1016/j.leukres.2011.06.008. Epub 2011 Jul 20.
6
Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis.
Haematologica. 2008 Jul;93(7):967-72. doi: 10.3324/haematol.13377.
7
Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.
Leukemia. 2012 Feb;26(2):356-8. doi: 10.1038/leu.2011.193. Epub 2011 Jul 29.
8
Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
Expert Rev Anticancer Ther. 2010 Oct;10(10):1663-72. doi: 10.1586/era.10.135.
9
A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
Leuk Res. 2009 Nov;33(11):e199-202. doi: 10.1016/j.leukres.2009.06.009. Epub 2009 Jul 9.
10
Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion.
Br J Haematol. 2010 Feb;148(3):483-4. doi: 10.1111/j.1365-2141.2009.07971.x. Epub 2009 Oct 28.
引用本文的文献
1
Current Management and New Developments in the Treatment of Myelodysplastic Syndrome.
Cancer Treat Res. 2021;181:115-132. doi: 10.1007/978-3-030-78311-2_7.
2
A primary care approach to myelodysplastic syndromes.
Korean J Fam Med. 2014 May;35(3):111-8. doi: 10.4082/kjfm.2014.35.3.111. Epub 2014 May 22.
3
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
Ann Hematol. 2014 Jan;93(1):1-11. doi: 10.1007/s00277-013-1863-5. Epub 2013 Sep 10.
4
NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes.
Leukemia. 2013 Oct;27(10):2077-81. doi: 10.1038/leu.2013.160. Epub 2013 May 27.
5
Important genes in the pathogenesis of 5q- syndrome and their connection with ribosomal stress and the innate immune system pathway.
Leuk Res Treatment. 2012;2012:179402. doi: 10.1155/2012/179402. Epub 2012 Feb 13.
6
L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway.
Blood. 2012 Sep 13;120(11):2214-24. doi: 10.1182/blood-2011-10-382986. Epub 2012 Jun 25.
本文引用的文献
1
A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome.
Nat Med. 2010 Jan;16(1):59-66. doi: 10.1038/nm.2063. Epub 2009 Nov 22.
2
Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype.
Nat Med. 2010 Jan;16(1):49-58. doi: 10.1038/nm.2054. Epub 2009 Nov 8.
3
Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Ann Hematol. 2010 Apr;89(4):365-74. doi: 10.1007/s00277-009-0846-z. Epub 2009 Oct 24.
4
Unimpaired terminal erythroid differentiation and preserved enucleation capacity in myelodysplastic 5q(del) clones: a single cell study.
Haematologica. 2010 Mar;95(3):398-405. doi: 10.3324/haematol.2009.012773. Epub 2009 Oct 8.
5
Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
Haematologica. 2009 Dec;94(12):1762-6. doi: 10.3324/haematol.2009.011528. Epub 2009 Oct 1.
6
Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.
Haematologica. 2010 Mar;95(3):406-14. doi: 10.3324/haematol.2009.010876. Epub 2009 Sep 22.
7
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12974-9. doi: 10.1073/pnas.0811267106. Epub 2009 May 26.
8
Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer.
Leukemia. 2009 Jul;23(7):1252-6. doi: 10.1038/leu.2009.53. Epub 2009 Mar 26.
9
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen.
Nature. 2008 Jan 17;451(7176):335-9. doi: 10.1038/nature06494.
10
Targeted therapies in myelodysplastic syndrome.
Semin Hematol. 2008 Jan;45(1):31-8. doi: 10.1053/j.seminhematol.2007.10.001.
Zotero 插件